Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01749605
Other study ID # 201005757
Secondary ID
Status Completed
Phase Phase 4
First received December 11, 2012
Last updated December 12, 2012
Start date October 2010
Est. completion date January 2012

Study information

Verified date December 2012
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority United States: University of Iowa Institutional Review Boards
Study type Interventional

Clinical Trial Summary

Pilot study to compare the efficacy and safety of 3-day, twice-daily regimens of nitrofurantoin and ciprofloxacin in emergency department (ED) patients presenting with UBC.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- pre-menopausal females

- ages 18-45 years old

- symptoms of a UTI (dysuria, frequency, urgency)

Exclusion Criteria:

- Onset of symptoms >7 days prior to the ED visit

- Non-English speaking

- Symptoms of pyelonephritis

- Diabetic

- Indications of sepsis

- Immunocompromised

- Currently using prophylactic antimicrobials

- Medications that could interfere with study drug

- Pregnant

- Lactating

- History of kidney or liver disease

- Vaginal symptoms

- Presence of a urinary catheter

- Treatment for UBC <2 weeks prior to ED visit

- Known allergy to study drug

- Unavailable for follow-up

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days

ciprofloxacin 250 mg BID x 3 days


Locations

Country Name City State
United States University of Iowa Hospitals and Clinics Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical cure at 7 days 7-day questionnaires included a table to measure the severity of the symptoms and their impact on daily life. Using this table, the investigators calculated a severity score (left hand column) and a bothersome score (right hand column), with a maximum score of 21 7 days No